Lineage Cell Therapeutics reported Q3 net income of $4.2 million, compared with a loss a year earlier, as a non-cash gain from warrant liability remeasurement offset lower revenue. Revenue fell due to reduced collaboration revenue from Roche and WDI.
Lineage Cell Therapeutics reported Q3 net income of $4.2 million, reversing a loss a year earlier. The result was driven by a non-cash gain from warrant liability remeasurement; income from operations was a loss of $7.3 million.
Revenue fell year over year, mainly because of lower collaboration revenue from Roche and WDI, reflecting fewer services provided. Operating expenses rose to $8.7 million as research and development spending on preclinical and Resonance programs increased, alongside higher general and administrative costs.
Lineage acquired NeuroAirmid, adding a Huntington’s disease cell therapy to its pipeline. The company expects initial COR1 preclinical data in Q1 2027 and expects cash and securities to support operations into Q2 2028; it plans to migrate HUNT1 to its AlloSCOPE platform for scalable production.
